Amphastar Pharmaceuticals, Inc.
AMPHNASDAQHealthcare● Active
$19.39
$-0.35(-1.77%)
Market Cap$854961699
P/E Ratio—
52W High$31.26
52W Low$16.65
Amphastar Pharmaceuticals, Inc. (AMPH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMPH · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.72B | $0.73B | $0.64B | $0.50B | $0.44B |
| Cost of Revenue | $0.36B | $0.36B | $0.29B | $0.25B | $0.24B |
| Gross Profit | $0.36B | $0.37B | $0.35B | $0.25B | $0.20B |
| Gross Margin %(computed) | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% |
| Operating Expenses | |||||
| R&D Expenses | $0.09B | $0.07B | $0.07B | $0.07B | $0.06B |
| G&A Expenses | $0.09B | $0.06B | $0.05B | $0.05B | $0.05B |
| Total Operating Expenses | $0.22B | $0.17B | $0.15B | $0.14B | $0.13B |
| Operating Income | $0.14B | $0.21B | $0.20B | $0.11B | $0.07B |
| Operating Margin %(computed) | 19.50% | 28.06% | 30.57% | 21.54% | 15.96% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.03B | $0.00B | $0.00B |
| Income Before Tax | $0.12B | $0.19B | $0.17B | $0.11B | $0.08B |
| Income Tax Expense | $0.03B | $0.03B | $0.03B | $0.02B | $0.02B |
| Net Income | $0.10B | $0.16B | $0.14B | $0.09B | $0.06B |
| Net Margin %(computed) | 13.63% | 21.79% | 21.34% | 18.31% | 14.19% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.10 | $3.29 | $2.85 | $1.88 | $1.30 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.15B | $0.28B | $0.24B | $0.15B | $0.11B |
| EBITDA Margin %(computed) | 20.71% | 37.89% | 37.29% | 29.29% | 25.48% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Amphastar Pharmaceuticals, Inc. data
About Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement
Amphastar Pharmaceuticals, Inc. (AMPH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AMPH reported revenue of $0.72B, gross profit of $0.36B (gross margin 49.46%), and net income of $0.10B — a net profit margin of 13.63%.
Frequently asked questions
AMPH · 4 questionsAmphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $0.72B for 2025, down 1.7% year-over-year.
AMPH revenueAMPH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08